Showing 3911-3920 of 5771 results for "".
- Omeros Completes Sale of Omidria Franchise to Rayner Surgicalhttps://modernod.com/news/omeros-completes-sale-of-omidria-franchise-to-rayner-surgical/2480536/Omeros announced that it has completed the sale of Omidria (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group. The transaction was completed pursuant to an Asset Purchase Agreement that was
- Global Data: Primary Open Angle Glaucoma Total Prevalent Cases to Reach 8.84 Million by 2030https://modernod.com/news/global-data-primary-open-angle-glaucoma-total-prevalent-cases-to-reach-884-million-by-2030/2480534/The burden of total prevalent cases (diagnosed and undiagnosed) of primary open angle glaucoma (POAG) is expected to increase at an annual growth rate (AGR) of 2% from around 7.3 million cases in 2020 to 8.84 million in 2030 in the seven major markets, according to GlobalData. The increase is par
- Rayner Appoints Ophthalmic Leaders as Strategic Advisors and is Awarded IDE for Trifocal IOLshttps://modernod.com/news/rayner-appoints-esteemed-ophthalmic-leaders-as-strategic-advisors-and-is-awarded-ide-for-trifocal-iols/2480533/Rayner has announced the appointment of Eric Donnenfeld, MD; Kerry Solomon, MD; Vance Thompson, MD; and Jim Mazzo as strategic advisors to the business, with a
- Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD)https://modernod.com/news/sight-sciences-receives-fda-510k-clearance-of-the-tearcare-system-for-treatment-of-meibomian-gland-dysfunction-mgd/2480531/Sight Sciences announced FDA 510(k) clearance of the TearCare System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication clears TearCare for the application of localized heat therapy in adult patients with
- Aldeyra Therapeutics to Modify Phase 3 TRANQUILITY -2 Trial in Dry Eye Disease After Missing Primary Endpointhttps://modernod.com/news/aldeyra-therapeutics-to-modify-phase-3-tranquility-trial-in-dry-eye-disease-after-missing-primary-endpoint/2480528/Aldeyra Therapeutics announced topline results from the Phase 3 TRANQUILITY trial of it investigational dry eye drug reproxalap. The primary endpoint of ocular redness was not met in TRANQUILITY, according to a company news release. However, statistical significance (P=0.0001) was
- Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops from Novartishttps://modernod.com/news/harrow-health-imprimisrx-acquires-us-commercial-rights-to-four-branded-eye-drops-from-novartis/2480527/Harrow Health, the parent company of ImprimisRx, announced its has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines—Iopidine 1% and 0.5% (apraclonidine hydroc
- CORE Names “Top 10 of 2021” Scientific Papers for Eye Care Communityhttps://modernod.com/news/core-names-top-10-of-2021-scientific-papers-for-eye-care-community/2480525/In a year like no other, the Centre for Ocular Research & Education (CORE) has published a record 66 scientific and clinical educational papers on topics that advance academic and clinical knowledge in optometry and ophthalmology. The organization today announced its “Top 10 o
- Haag-Streit to Focus on Surgical Microscopes in Ophthalmologyhttps://modernod.com/news/haag-streit-to-focus-on-surgical-microscopes-in-ophthalmology/2480524/Haag-Streit announced that it was focus its business moving forward on ophthalmology—discontinuting its surgical product portfolio in neurosurgery, spine surgery, ENT and plastic-reconstructive surgery. "For our customers, this focus on eye care will allow us to offer so
- Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseaseshttps://modernod.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/The Foundation Fighting Blindness announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation. The program will provide funding for six early translational research projects over 3 years for the dev
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin